Clinical Trial Update: Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating how rivaroxaban affects inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Peripheral Artery Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: LifeBridge Health | Conditions: Coronary Artery Disease, Peripheral Artery Disease | Phase 4 | Status: UNKNOWN